HSPG2 overexpression independently predicts poor survival in patients with acute myeloid leukemia
Autor: | Jianxiang Chi, Simin Liang, Li Wang, Qian Zhan, Li Yang, Xiaojia Zhou |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Adolescent Angiogenesis Immunology CD34 Article Statistics Nonparametric Metastasis Tumour biomarkers Cohort Studies Cellular and Molecular Neuroscience Prognostic markers Young Adult Internal medicine White blood cell hemic and lymphatic diseases Cell Line Tumor Medicine Humans Progenitor cell lcsh:QH573-671 Child Aged Aged 80 and over business.industry lcsh:Cytology Gene Expression Regulation Leukemic Myeloid leukemia Cell Biology Middle Aged medicine.disease Survival Analysis Haematopoiesis Leukemia Myeloid Acute medicine.anatomical_structure Treatment Outcome ROC Curve Case-Control Studies Multivariate Analysis Female Bone marrow business Heparan Sulfate Proteoglycans |
Zdroj: | Cell Death & Disease Cell Death and Disease, Vol 11, Iss 6, Pp 1-11 (2020) |
ISSN: | 2041-4889 |
Popis: | Heparan sulfate proteoglycan 2 (HSPG2), also known as perlecan, is a large multi-domain extracellular matrix proteoglycan, which contributes to the invasion, metastasis and angiogenesis of solid tumor. However, very little is known about the effect of HSPG2 on acute myeloid leukemia (AML). This study aims to investigate the prognostic value of the HSPG2 gene in terms of overall survival and leukemia-free survival in patients with AML. Bone marrow mononuclear cells (BMMCs) from 4 AML patients and 3 healthy controls were processed for RNA-Sequencing (RNA-seq). The mRNA expression level of HSPG2 in BMMCs and CD34+ hematopoietic stem/progenitor cells (HSPC) obtained from enrolled participants and human leukemic cell lines was detected by RT-qPCR. Then the correlations between the expression of HSPG2 and a variety of important clinical parameters, such as median white blood cell (WBC) count and bone marrow (BM) blasts, were further analyzed. The expression level of HSPG2 was significantly upregulated in AML patients at the time of diagnosis, downregulated after complete remission and then elevated again at relapse. Moreover, HSPG2 expression was associated with median WBC count (P P = 0.02), median platelet count (P = 0.001), and BM blasts (P P = 0.001) and poorer leukemia-free survival (LFS) (P = 0.047). In the multivariate analysis model, HSPG2 was identified as an independent prognostic biomarker of AML. Taken together, these results indicate that HSPG2 overexpression was associated with poor prognosis in AML patients, and may be a prognostic biomarker and therapeutic target of AML. |
Databáze: | OpenAIRE |
Externí odkaz: |